ZM323881 is an anilinoquinazoline that potently inhibits VEGFR2 (KDR) tyrosine kinase activity and demonstrates excellent selectivity compared with other receptor tyrosine kinases, including PDGFRβ, FGFR1, EGFR and erbB2 (IC 50 >50 μM). ZM323881 inhibits VEGF-A-induced endothelial cell proliferation(IC 50 =8 nM) and VEGFR2 tyrosine phosphorylation [1]. ZM323881 inhibits activation of VEGFR-2, but not of VEGFR-1, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or hepatocyte growth factor (HGF) receptor. In HAECs, ZM323881 completely inhibits VEGF-induced ERK phosphorylation at 1 μM [2].